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Abstract: Overactive bladder (OAB) is a highly prevalent condition, affecting males and 
females. The prevalence increases with age. Behavioral therapy and antimuscarinic therapy 
remain the first-line therapies for management of OAB. Despite improvements in symptoms, 
persistence with antimuscarinic therapy has remained low. Multiple factors including patient 
expectations, adverse effects and cost may affect persistence. Fesoterodine is one of the newest 
antimuscarinic agent approved for the management of OAB. It is unique in that it shares the 
same active metabolite as tolterodine, 5-hydoxymethyltolterodine (5-HMT); however, this 
conversion is established via ubiquitous esterases and not via the cytochrome P450 system, 
thus providing a faster and more efficient conversion to 5-HMT. Fesoterodine is available in 2 
doses, 4 mg and 8 mg. Clinical trials have established a dose response relationship in efficacy 
parameters as well as improvements in quality of life. As with all antimuscarinics, dry mouth 
and constipation are the more common side effects. A combination of medical therapy and 
behavioral therapy improves the overall outcome in management of OAB. Dose flexibility may 
help improve efficacy outcomes and patient education on the management of common adverse 
effects may improve tolerability with these agents.
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Introduction
Overactive bladder (OAB) is a syndrome complex composed the following symptoms, 
urgency with or without urgency urinary incontinence (UUI), often in the presence of 
urinary frequency and nocturia. The term, developed by the International Continence 
Society, is suggestive of underlying detrusor overactivity, but may be related to other 
forms of urethrovesical dysfunction. The term in its strict sense, refers to idiopathic 
OAB, a condition that occurs in the absence of other conditions that may cause or 
mimic the symptoms.1 OAB is a chronic condition that has a significant impact on 
health related quality of life and may require life-long treatment.2,3
Epidemiologic studies throughout the world have highlighted the prevalence of 
this condition. The prevalence rates in the United States and Europe range from 12% 
to 17%. The prevalence of OAB is similar in males and females, and the prevalence 
increases with age in both sexes.4–6 Despite the high prevalence, only a small percent-
age of patients are evaluated and treated.4 A variety of factors, both physician and 
patient-related may affect this apparent under-diagnosis and under-treatment.
OAB has a huge impact on quality of life. However, the impact of OAB extends well 
beyond its impact on quality of life (QOL). Individuals with OAB are at greater risk 
for urinary tract infections, may have altered sleep, have a greater risk for depression7 Therapeutics and Clinical Risk Management 2009:5 870
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and in those with associated urinary incontinence, a greater 
likelihood of perineal dermatitis. Elderly women with OAB 
and urinary incontinence are at greater risk for falls and 
fractures, 26% and 34 %, respectively.8,9 In 1995 the amount 
spent for tangible OAB-related care was US$12.6 million in 
the United States.10,11 A recent population-based survey was 
used to calculate disease-specific total costs for OAB for 
individuals who responded to the survey as having “often” 
OAB symptoms. The disease specific cost of OAB was esti-
mated at US$24.9 billion.12 This economic burden can only 
be expected to rise as our population ages and grows.
The management of OAB symptoms has relied primarily 
on pharmacologic therapy with or without behavioral therapy. 
Antimuscarinic agents are the only approved agents for the 
management of OAB. Their efficacy in decreasing OAB 
symptoms and improving QOL has been demonstrated.13 
Historically, the use of antimuscarinic therapy has been 
limited by the presence of intolerable side effects and lack of 
sufficient response in some individuals. Alterations in drug 
formulations such as once daily dosing, dose flexibility, and 
medications with greater selectivity for muscarinic receptors 
in the bladder as opposed to other areas in the body have 
improved the tolerability profile and ease of use of these 
agents. Yet, many patients remain on therapy for less than 
a year. Reasons for the lack of continued use may include 
insufficient treatment response, unacceptable tolerability, and 
cost. Identifying the patient’s treatment goals and ensuring 
that they are reachable goals, is important to the success of 
antimuscarinic therapy. In addition, proactively managing 
potential adverse effects may also decrease future discon-
tinuation rates.
Currently, there are 11 different formulations of anti-
muscarinic agents approved by the FDA for the pharmaco-
logic management of OAB (Table 1). Fesoterodine is one 
of the most recent antimuscarinic agents to be approved by 
the FDA. All of these agents are efficacious in the manage-
ment of OAB, decreasing micturition frequency, urgency 
severity and urgency incontinence episodes and increasing 
the volume voided with each micturition. Comparisons 
of efficacy between the agents are limited by the lack of 
a significant number of head to head trials. Differences, 
albeit in some cases subtle, exist between the agents 
in their delivery systems, metabolism, dose flexibility, 
and side effect profiles. These differences may allow for 
prescribing variability depending on patient’s underlying 
medical conditions and provides for alternative agents in 
the setting of poor tolerability and/or efficacy with the 
initial antimuscarinic therapy.
Pathophysiology of OAB and 
rationale for antimuscarinic agents
The cause of idiopathic OAB is not known. Neurogenic, 
myogenic and combined etiologies have been proposed.14 
Historically, emphasis was placed on the role of the effer-
ent pathway in OAB symptoms. However, abnormalities in 
the afferent pathway and/or in the central nervous system 
have been proposed as other possible etiologies of OAB.15 
The muscarinic receptor has been the major peripheral 
pharmacological target in treating OAB.16 In the efferent 
pathway, acetylcholine, released from parasympathetic 
presynaptic nerve terminals binds to muscarinic receptors 
in the detrusor muscle to stimulate a detrusor contraction. 
Although there are 5 different muscarinic receptors located 
throughout the body (M1–M5),16 in the bladder, the M2 and 
M3 receptors predominate. The M2 receptor accounts for 
80% of the muscarinic receptors in the detrusor M3 20%.16 
The M3 receptor appears to have the primary role in normal 
detrusor contraction. M2 receptors appear to indirectly 
reverse sympathetically mediated smooth muscle relaxation. 
In certain diseased states, M2 receptors may also contrib-
ute to direct smooth muscle contraction.17 More recently 
muscarinic receptors have been identified in the urothelium 
and suburothelium. The role of these muscarinic receptors is 
not well understood but it is theorized that they may play a 
role in afferent pathway mediated OAB symptoms.18,19
Pharmacology and 
pharmacokinetics of fesoterodine
Fesoterodine is one of the newer antimuscarinic agents 
approved for the treatment of OAB. It is unique in that it 
shares the same active metabolite as tolterodine. A matrix 
Table 1 Currently approved antimuscarinic agents for overactive 
bladder
Generic name Brand name
Oxybutynin Ditropan
Oxybutynin extended release Ditropan XL
Oxybutynin patch Oxytrol
Oxybutynin gel Gelnique
Tolterodine immediate release Detrol
Tolterodine extended release Detrol LA
Solifenacin vesicare
Darifenacin Enablex
Trospium chloride immediate release Sanctura
Trospium chloride extended release Sanctura XR
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platform is used for the extended release delivery of once daily 
fesoterodine. Upon ingestion, the outer polymer layer swells 
to form a gel layer surrounding the tablet which controls the 
release of fesoterodine, thus the tablet cannot be cut crushed 
or chewed.20 Taking the drug in a fed or fasted state does 
not appear to have a significant effect.20,21 The metabolism 
of fesoterodine to the active metabolite, 5-HMT, is via 
rapid hydrolysis by ubiquitous, non-specific esterases which 
are present throughout the body.20,22–24 Tolterodine is also 
metabolized to 5-HMT, however this is via the cytochrome 
P450 system. The metabolism of fesoterodine is rapid and 
extensive, such that fesoterodine cannot be detected in 
plasma after oral administration.20,23 Thus, fesoterodine is 
a pro-drug.25 Esterases are consistent among individuals, 
and their activity is not affected by other drugs, thus 
eliminating two sources of variability in exposure to the drug 
among different patients.26,27 5-HMT has linear and dose-
proportional pharmacokinetics. 5-HMT is eliminated via 
one of three routes, it is metabolized in the liver to inactive 
metabolites by the CYP3A4 or CYP2D6 pathway28,29 and 
approximately 16% of 5-HMT is excreted unchanged in the 
urine.20 Fesoterodine is available in 2 doses, 4 mg and 8 mg. 
Studies have demonstrated a dose-dependent response with 
fesoterodine in the reduction of OAB symptoms.30,31
Efficacy of fesoterodine
Two phase III multicenter, randomized, double-blind, 
placebo-controlled studies were performed to assess the 
clinical efficacy, safety and tolerability of once-daily 
fesoterodine in patients with OAB.32,33 All subjects had 
increased urinary frequency and urgency and/or UUI. The 
primary efficacy variable was a change from baseline to 
week 12 in micturitions per 24 hours. Co-primary endpoints 
included change from baseline to week 12 in UUI episodes 
per 24 hours and treatment response (“yes” or “no”, based 
on a 4-point treatment benefit scale). Secondary efficacy 
variables included mean volume voided per micturition, 
continent days per week and number of urgency episodes. 
Patients were randomized to placebo, 4 mg of fesoterodine, 
and 8 mg fesoterodine in the US study,32 whereas in the 
European study there was an active control arm, tolterodine 
extended release (ER) 4 mg.33
US study
A total of 836 subjects were randomized and included in the 
full analysis set population, 76% of whom were female. The 
mean age was 59 years (range 21 to 91 years). Approximately 
50% of the subjects had received prior OAB treatment and 
81% of the patients were incontinent at the time of placebo 
run-in. Treatment with 4 mg and 8 mg FESO resulted in 
statistically significant and clinically relevant improve-
ments compared to placebo in the 2 co-primary endpoints 
(P  0.05). In addition, the mean change from baseline in 
the number of micturitions and UUI episodes per 24 hours 
was significantly improved with both doses of fesoterodine 
compared to placebo. Analysis of secondary endpoints 
demonstrated significant improvements with 4 mg of fes-
oterodine compared to placebo for mean change from base-
line in urgency episodes and continent days per week (each 
P  0.001), whereas 8 mg of fesoterodine was significantly 
better than placebo for mean volume voided per micturition, 
number of urgency episodes, number of daytime micturitions 
and continent days per week (each P  0.001)32 (Table 2).
European study
A total of 1132 patients were enrolled and received study 
medication. Similar to the US study, the mean age was 
57 years and most patients were women (80%) with 75% 
to 81% of subjects reporting urge urinary incontinence on 
the baseline diary. The mean number of micturitions was 
significantly reduced from baseline for subjects taking 
tolterodine ER 4 mg, fesoterodine 4 mg and fesoterodine 
8 mg compared to placebo (P  0.001 for each). The 
mean reduction from baseline in urge urinary incontinence 
episodes per 24 hours was significantly greater for toltero-
dine ER (P = 0.008), fesoterodine 4 mg (P = 0.001) and 
fesoterodine 8 mg (P  0.001) compared to placebo. The 
mean volume voided was also significantly increased for 
tolterodine ER (P = 0.002), fesoterodine 4 mg (P  0.001), 
fesoterodine 8 mg (P  0.001) compared to placebo. Statis-
tically significant reduction in the number of UUI episodes 
per 24 hours were seen with tolterodine ER (P = 0.004), 
fesoterodine 4 mg (P = 0.002) and 8 mg fesoterodine 
(P  0.001), whereas significant increases in the number of 
continent days per week were seen with 4 mg fesoterodine 
(P = 0.007) and 8 mg fesoterodine (P  0.001) compared 
to placebo33 (Table 2).
Post-hoc analyses
Female subjects
A post-hoc analysis of pooled data from the 2 clinical trials 
involving 1548 women was performed to assess the efficacy 
and tolerability of fesoterodine in women. In this analysis, 
fesoterodine 8 mg was significantly more efficacious than 
fesoterodine 4 mg and tolterodine ER 4 mg in improving 
UUI episodes and continent days per week.34Therapeutics and Clinical Risk Management 2009:5 872
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Fesoterodine 8 mg vs tolterodine ER 4 mg
A post-hoc inferential analysis was conducted on the primary 
endpoint (micturitions/24 hours), the two co-primary end-
points (UUI episodes/24 hours and treatment response), 
several secondary endpoints (including continent days per 
week and mean volume voided) comparing patients receiving 
fesoterodine 8 mg and tolterodine ER 4 mg in the phase III 
European trial. Fesoterodine 8 mg was statistically significantly 
better than tolterodine ER 4 mg for improving urgency UUI 
episodes, mean volume voided and number of continent days 
per week.35
Fesoterodine 4 mg vs fesoterodine 8 mg
A pooled analysis of the data from the 2 phase III clinical 
trials for patients receiving fesoterodine 4 mg, fesoterodine 
8 mg and placebo was performed. At the end of treatment, 
both doses of fesoterodine showed statistically significant 
improvements in all efficacy endpoints vs placebo (P  0.01). 
These effects were seen 2 weeks after initiation of treatment 
(the earliest evaluation point) and were sustained throughout 
the treatment period. Fesoterodine 8 mg performed signifi-
cantly better than fesoterodine 4 mg in improving all diary 
variables (P  0.05) except micturition frequency, demon-
strating a dose-response relationship.36
Tolerability and safety 
of fesoterodine
The safety and tolerability of fesosterodine have been 
evaluated in phase II and III controlled trials involving 
2859 OAB patients, of which 2288 were treated with 
fesoterodine. Approximately 80% of these individuals 
were treated with fesoterodine for 10 weeks. In these 
studies, the incidence of serious adverse events in patients 
receiving placebo fesoterodine 4 mg and fesoterodine 8 mg 
were 1.9%, 3.5% and 2.9%, respectively. In only 4 patients 
receiving fesoterodine were the serious adverse events 
felt to be related or likely due to study medication. Each 
of these 4 patients had 1 reported serious adverse event: 
angina, chest pain, and gastroenteritis, and QT prolonga-
tion on ECG.
The most commonly reported adverse event in patients 
treated with fesoterodine, was dry mouth, a commonly 
reported side effect of antimuscarinic therapy. The incidence 
of dry mouth varied from 19% for those taking fesoterodine 
4 mg to 35% taking fesoterodine in the fixed dose studies, 
compared to 7% for placebo. In most cases, the dry mouth was 
mild or moderate and discontinuations related to dry mouth 
were 0.4%, 0.4% and 0.8% in patients receiving placebo, 
fesoterodine 4 mg and fesoterodine 8 mg, respectively. 
Table 2 Phase III clinical trials – efficacy results20




Placebo US Fesoterodine  
4 mg US
Fesoterodine   
8 mg US
Micturitions/24 h
  Baseline 12.0 11.6 11.9 12.2 12.9 12.0
  Mean change -0.95 -1.76* -1.88* -1.08 -1.61* -2.09*
  Median % change -11.1 -16.7* -18.6* -6.9 -14.9* -15.0*
UUi episodes/24 h
  Baseline 3.7 3.8 3.7 3.7 3.9 3.9
  Mean change -1.14 -1.95* -2.22* -0.96 -1.65* -2.28*
  Median % change -80.0* -87.5* -67.4* -81.8*
Mvv/mL
  Baseline mean 150.2 160.0 153.9 159 152 156
  Mean change 9.37 27.72* 33.62* 8.38 16.5 33.6*
Urgency episodes/24 h
  Baseline 11.4 11.0 11.5 11.4 12.5 11.6
  Mean change -1.07 -1.88* -2.36* -0.79 -1.91* -2.30*
  Median % change -11.1 -17.6* -19.1* -3.3 -16.3* -18.4*
Continent days/wk
  Baseline mean 0.8 0.8 0.6 0.6 0.7 0.7
  Mean change 2.07 2.84* 3.32* 1.31 2.33* 2.80*
*Statistically significant compared to placebo.
Abbreviations: Mvv, mean volume voided; UUi, urgent unrinary incontinence.Therapeutics and Clinical Risk Management 2009:5 873
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Constipation was reported in 2% of subjects taking placebo, 
4% in those taking fesoterodine 4 mg and 6% in those taking 
8 mg of fesoterodine. Dry eyes were reported in 0% patients 
taking placebo, 1.4% on fesoterodine 4 mg and 3.7% taking 
fesoterodine 8 mg.20
Three-year open-label extension trials after 1 phase II and 
both phase III controlled trials demonstrated similar adverse 
events as reported in the 12-week, placebo-controlled stud-
ies. As with the controlled trials, most cases of dry mouth 
and constipation were mile to moderate in intensity. Seri-
ous adverse events deemed to be at least possibly related 
to study medication by the investigator and reported more 
than once in the open-label treatment period of up to 3 years 
included urinary retention (3 cases), diverticulitis (3 cases), 
constipation (2 cases), irritable bowel syndrome (2 cases) 
and electrocardiogram QT corrected interval prolongation 
(2 cases).20
Effects on QT interval
A double-blind, placebo-controlled, parallel-group study 
involving 261 healthy subjects was performed to assess 
effects of fesoterodine on the QT interval. Individuals 
received fesoterodine 4 mg or 28 mg, placebo or moxifloxacin 
(a positive control). There was no effect of fesoterodine on 
the QT interval at the 4 mg dose or 28 mg dose. Additional 
assessments of the QT interval in other fesoterodine clinical 
trials did not show any increase in the QT interval.20
Heart rate
In the two phase III trials, the mean increase in heart rate 
compared to placebo was approximately 3 to 4 beats per 
minute in the 4 mg/day group and 3 to 5 beats per minute in 
the 8 mg/day group.20
Contraindications and precautions
As with all antimuscarinic agents approved for the use of 
OAB, fesoterodine is contraindicated in patients with urinary 
retention, gastric retention, or uncontrolled narrow-angle 
glaucoma. It is also contraindicated in patients with a known 
hypersensitivity to the drug or its metabolites. Fesoterodine 
should be used with caution in patients with clinically sig-
nificant bladder outlet obstruction, decreased gastrointestinal 
motility, patients with controlled narrow-angle glaucoma and 
patients with myasthenia gravis.
In patients with mild to moderate hepatic impairment, 
there is no need to adjust the dose of fesoterodine. How-
ever, as it has not been studied in patients with severe 
hepatic impairment its use is not recommended in this 
patient population. In individuals with mild or moderate 
renal insufficiency there is no dosage adjustment required, 
however, doses greater than 4 mg are not recommended in 
patients with severe renal insufficiency.
Doses of fesoterodine greater than 4 mg are not recom-
mended in patients taking potent CYP3 A 4 inhibitors such 
as ketoconazole, itraconazole and clarithromycin. In patients 
taking weak or moderate CYP3A4 inhibitors such as eryth-
romycin, careful assessment of tolerability at the 4 mg daily 
dose is recommended before increasing to 8 mg.
When used in conjunction with other antimuscarinics, 
the antimuscarinic side effects may be potentiated. Anticho-
linergic agents can potentially alter the absorption of some 
concomitantly administered drugs due to anticholinergic 
effects on gastrointestinal motility.20
There is no dosage adjustment recommended for age, 
gender or race.
Patient-reported outcomes
OAB is a condition which has a significant impact on quality 
of life. Although assessment of voiding diary parameters, 
particularly volume voided, provide objective measures of 
treatment response, it is the patient’s perception of treatment 
benefit and the effects on his/her quality of life that often 
impacts on whether or not a patient will continue with therapy. 
Each patient may have individual treatment expectations and 
thus when evaluating and managing patient’s with OAB it is 
important to identify the patient’s treatment expectations to 
ensure they are realistic and to identify such factors which 
will govern their assessment of response to therapy.
US phase iii clinical trial – patient 
reported outcomes
The King’s Health questionnaire (KHQ), the international 
consultation of incontinence questionnaire, short-form 
(ICIQ-SF) and a Likert scale assessment of bladder-related 
problems were completed by patients at baseline and at week 
12 of treatment. The KHQ is a validated disease specific 
quality of life questionnaire assessing QOL in women with 
urinary incontinence. It comprises 21 items divided into 
9 domains: severity (coping), emotions, role limitations, 
physical limitations, social limitations, sleep/energy, personal 
relationship, impact on life and general health.37,38 Both active 
arms in the study (fesoterodine 4 mg and 8 mg) demonstrated 
greater improvements in subjects’ quality of life compared 
to placebo. The 8 mg dose of fesoterodine produced signifi-
cantly greater improvement over placebo in 7 of the 9 KHQ 
domains (P  0.05; all domains except general health Therapeutics and Clinical Risk Management 2009:5 874
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and personal relationships). Fesoterodine 4 mg produced 
significantly greater improvement compared to placebo on 
2 out of 9 KHQ domains. The ICIQ-SF is a validated incon-
tinence-specific quality of life questionnaire that consists of 
3 scored items (the frequency of leakages, usual amounts of 
leakages and the impact on daily life). The total score is a 
sum of the 3 scored items yielding a score ranging from 0 
to 21, with higher scores indicating more significant incon-
tinence and impact.39 Both doses of fesoterodine produced 
significantly greater improvements compared to placebo on 
ICIQ-SF scores (P  0.0025). In addition, the proportion of 
subjects reporting improvement in their bladder-related prob-
lems on the Likert scale was statistically significantly greater 
than placebo in both fesoterodine arms, 4 mg (P = 0.0175) 
and 8 mg (P = 0.0005), based on the 3-category analysis 
of the changes from baseline (improvement, no change, 
or deterioration). There was a 54.5% and 62.3% improve-
ment in the Likert scale with fesoterodine 4 mg and 8 mg, 
respectively, compared to 46% with placebo.40
Pooled data from the two phase iii 
clinical trials
Pooled data from two randomized placebo-controlled phase III 
studies were analyzed. Eligible patients with frequency and 
urgency or urgency urinary incontinence were random-
ized to placebo or fesoterodine 4 or 8 mg for 12 weeks; 
one trial also included tolterodine ER 4 mg. HRQoL was 
assessed using the KHQ, ICIQ-SF, a six-point Likert scale 
measuring the severity of bladder-related problems, and 
treatment response.
By the end of treatment, all active-treatment groups 
had significantly improved HRQoL compared with those 
on placebo, as shown by an improvement in the KHQ 
and ICIQ-SF scores, treatment response rate, and a major 
improvement in self-reported bladder-related problems. 
The fesoterodine 8-mg group had statistically significant 
improvements over placebo in 8 of 9 KHQ domains. 
Fesoterodine 4 mg and tolterodine ER produced statistically 
significant improvements in 7 of 9 KHQ domains compared 
to placebo. Fesoterodine 8 mg gave better results than 4 mg 
in 2 domains; Emotions and Symptom Severity (P  0.05). 
A major improvement (2 points) in bladder-related prob-
lems was reported by 33% of patients on fesoterodine 4 mg, 
38% on fesoterodine 8 mg, and 34% on tolterodine ER, 
vs 21% on placebo (P  0.001).41
Effects of flexible dose fesoterodine on treatment sat-
isfaction and quality of life were evaluated in a 12-week, 
multi-center, open-label, single arm, flexible dose study.42 
Five hundred and sixteen subjects participated in the study 
and started on 4 mg of fesoterodine. At week 4 they could 
either continue on 4 mg of fesoterodine or increase to 8 mg 
of fesoterodine. Patient treatment satisfaction and quality of 
life were assessed with the treatment satisfaction question-
naire, the patient perception of bladder condition (PPBC) and 
the OAB questionnaire (OAB-q). The PPBC is a single item, 
6 point instrument used by subjects to rate severity of their 
bladder related problems, ranging from my bladder causes 
me no to many severe problems.43 The OAB-q is an 8 item 
symptom bother scale and a 25-item health related quality of 
life scale with 4 domains (concern, coping, sleep and social 
interaction).39 Approximately 50% of the subjects opted to 
dose escalate at week 4. Approximately 80% of the subjects 
who responded to the treatment satisfaction question at week 
12 reported satisfaction with treatment, 38% being very satis-
fied. Using the PPBC, 83% of subjects reported improvement 
at week 12 with 59% reporting improvements of 2 points. 
Significant improvements from baseline were noted in OAB-q 
symptom bother and health related quality of life scales and 
all 4 health related quality of life domains.42
Conclusions
Overactive bladder is a highly prevalent condition associated 
with significant impact on quality of life, associated morbidi-
ties and cost. Antimuscarinic agents remain one of the first 
line therapies for treatment. Use of antimuscarinic agents in 
combination with behavioral therapy is more effective than 
either therapy used alone. Fesoterodine is the newest antimus-
carinic agent approved for the treatment of OAB. In addition 
to the statistically significant improvements seen in voiding 
diary parameters with both 4 mg and 8 mg of fesoterodine 
compared to placebo, a dose-dependent response was noted 
between 4 mg and 8 mg of fesoterodine. This dose response 
has not been demonstrated with all of the other antimuscarinic 
agents that offer multiple doses. Only oxybutynin has shown 
statistically significant differences between the 15 mg dose 
and the 2 lower doses (5 mg, 10 mg) for reduction of urgency 
urinary incontinence episodes and mean volume voided per 
micturition.44 Dose separation has not been demonstrated 
for efficacy outcomes with darifenacin45,46 solifenacin47 and 
tolterodine48,50 Both doses of fesoterodine have demonstrated 
significant improvements in patients’ perception of treatment 
outcomes as reflected by the treatment response questionnaire 
and the PPBC. In addition, statistically significant improve-
ments in HRQoL have been demonstrated for both doses using 
the KHQ and the OAB-q. The improvements in OAB symp-
toms and quality of life are complemented by its favorable Therapeutics and Clinical Risk Management 2009:5 875
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tolerability and safety profile. Dry mouth, the most common 
side effect, tends to be mild to moderate in nature and led to 
few discontinuations in clinical trials. There are relatively few 
situations in which fesoterodine is not recommended or in 
which require dosage limitations are recommended.
Despite the number of antimuscarinic therapies available 
to patients and the ability to try alternative antimuscarinic 
therapies, some patients will ultimately fail antimuscarinic 
therapy. Neuromodulation via a surgically implanted device 
(Interstim, Medtronics) or via percutaneous routes (percu-
taneous tibial nerve stimulation) are approved options for 
the management of OAB and are typically employed as 
second-line therapies. Injection of botulinum toxin into the 
detrusor for the treatment of OAB remains investigational. 
A greater understanding of the role of the urothelium and 
suburothelium and the central nervous system and their pos-
sible roles in OAB symptoms has prompted investigation of 
agents that may modulate the afferent pathway and central 
nervous system pathways of OAB.
Disclosure
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